Log in

CVE:QPTQuest PharmaTech Stock Price, Forecast & News

C$0.18
0.00 (0.00 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
C$0.18
Now: C$0.18
C$0.18
50-Day Range
C$0.13
MA: C$0.18
C$0.25
52-Week Range
C$0.06
Now: C$0.18
C$0.28
Volume3,500 shs
Average Volume37,099 shs
Market CapitalizationC$30.19 million
P/E Ratio0.30
Dividend YieldN/A
BetaN/A
Quest PharmaTech Inc., a biotechnology company, develops and commercializes antibody based immunotherapeutic products for cancer. It operates in two segments, Biopharmaceutical/Pharmaceutical Products and Consumer/Cosmetic Products. The company focuses on combinatorial immunotherapeutic approaches to cancer by using monoclonal antibodies of the immunoglobulin G or E subclass in combination with chemotherapy/immune-adjuvant. Its lead product candidate is Oregovomab, a monoclonal antibody, which is in Phase II clinical trial for the treatment of ovarian cancer. The company also owns the Photodynamic therapy technology for oncology and dermatology applications; and markets Bellus Skin serum, an anti-wrinkle skin care product, as well as develops Mab AR 9.6 against truncated O-glycan on MUC16 for targeted cancer therapy applications. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.80 out of 5 stars


Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-780-4481400

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesC$38,871.00
Cash FlowC$0.00 per share
Book ValueC$0.63 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$30.19 million
Next Earnings Date9/16/2020 (Estimated)
OptionableNot Optionable

Receive QPT News and Ratings via Email

Sign-up to receive the latest news and ratings for QPT and its competitors with MarketBeat's FREE daily newsletter.

Quest PharmaTech (CVE:QPT) Frequently Asked Questions

How has Quest PharmaTech's stock been impacted by COVID-19 (Coronavirus)?

Quest PharmaTech's stock was trading at C$0.11 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QPT shares have increased by 63.6% and is now trading at C$0.18. View which stocks have been most impacted by Coronavirus.

When is Quest PharmaTech's next earnings date?

Quest PharmaTech is scheduled to release its next quarterly earnings announcement on Wednesday, September 16th 2020. View our earnings forecast for Quest PharmaTech.

Has Quest PharmaTech been receiving favorable news coverage?

News coverage about QPT stock has been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Quest PharmaTech earned a coverage optimism score of -1.8 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Quest PharmaTech.

Who are some of Quest PharmaTech's key competitors?

What other stocks do shareholders of Quest PharmaTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest PharmaTech investors own include Canadian Metals (CME) and Aphria (APHA).

Who are Quest PharmaTech's key executives?

Quest PharmaTech's management team includes the following people:
  • Dr. Ragupathy Madiyalakan, CEO & Director
  • Mr. Pierre Vermette, Chief Financial Officer
  • Mr. Thomas Woo, VP of Product Devel.
  • Mr. Roger Andrews, Head of Investor Relations & Corp. Communications
  • Mr. Douglas C. Bachman, VP of Corp. Devel. (Age 65)

What is Quest PharmaTech's stock symbol?

Quest PharmaTech trades on the Canadian Venture Exchange (CVE) under the ticker symbol "QPT."

How do I buy shares of Quest PharmaTech?

Shares of QPT and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Quest PharmaTech's stock price today?

One share of QPT stock can currently be purchased for approximately C$0.18.

How big of a company is Quest PharmaTech?

Quest PharmaTech has a market capitalization of C$30.19 million and generates C$38,871.00 in revenue each year.

What is Quest PharmaTech's official website?

The official website for Quest PharmaTech is www.questpharmatech.com.

How can I contact Quest PharmaTech?

Quest PharmaTech's mailing address is 8123 Roper Rd NW, EDMONTON, AB T6E 6S4, Canada. The company can be reached via phone at +1-780-4481400.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.